New IV iron and phosphate binder products poised for launch
Nephrologists can expect some new IV iron and phosphate binder products to be launched this year
A new report by BioTrends Research Group predicts that some new products may be launched in the IV iron and hyperphosphatemia markets this year. The Exton, Pa., firm said that a new form of intravenous iron, ferumoxytol, from AMAG Pharmaceuticals could be available in the second half of this year. In a survey of 305 clinical nephrologists that BioTrends did last December, it found that 68% are not familiar with this product. BioTrends added that in the phosphate binder market, respondents feel that there is a strong need for new products, but knowledge of new binders, such as Genzyme's recently approved Renvela (sevelamer carbonate), is low. Renvela is expected to launch in the first quarter.
To see more Daily News articles, click here.
To go to the Drug Topics homepage, click here.
